{"id":"NCT00329797","sponsor":"Radiation Therapy Oncology Group","briefTitle":"Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy","officialTitle":"A Phase III Randomized Study to Evaluate the Efficacy of ZometaÂ® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2006-05-25","resultsPosted":"2017-11-29","lastUpdate":"2017-11-29"},"enrollment":109,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Osteoporosis","Prostate Cancer"],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"Calcium","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Zoledronic acid","otherNames":["Zometa","zoledronate"]},{"type":"RADIATION","name":"radiation therapy","otherNames":[]},{"type":"DRUG","name":"LHRH","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin D","otherNames":[]}],"arms":[{"label":"Zoledronic Acid","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with prostate cancer.\n\nPURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with locally advanced nonmetastatic prostate cancer undergoing radiation therapy and hormone therapy.","primaryOutcome":{"measure":"Freedom From Any Bone Fracture (FABF) Rate at Three Years","timeFrame":"From randomization to 3 years","effectByArm":[{"arm":"Zoledronic Acid","deltaMin":98,"sd":null},{"arm":"Control","deltaMin":97.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.95"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":50},"commonTop":["Hot flushes NOS","Fatigue","Pollakiuria","Hemoglobin","Arthralgia"]}}